Eli Lilly and Company

Patrick Gianpietro Spinazze

Vincent Patrick Rocco

John Xiaoqiang He

Kumiko Takeuchi

Freddie Craig Stevens

Todd Jonathan Kohn

Nicholas Allan Honigschmidt

Daniel Jon Sall

Jolie Anne Bastian

Theo Schotten

Cynthia Darshini Jesudason

Don Richard Finley

Andrew Michael Ratz

John Arnold Werner

William George Trankle

Gerd Reuhter

John M Schaus

David Andrew Coates

Richard Duane Johnston

Steven Marc Massey

Kevin Matthew Gardinier

Douglas Richard Stack

Timothy Barrett Durham

James Lee Toth

Marta Maria Pineiro-Nunez

James E Audia

Paul Leslie Ornstein

Thomas Daniel Aicher

Jon Kevin Reel

David Edward Tupper

Peter Thaddeus Gallagher

Warren Jaye Porter

Albert Kudzovi Amegadzie

Thomas Charles Britton

Sandra Ann Filla

Barry P Clark

Erik James Hembre, Ii

Jianliang Lu

Sean Patrick Hollinshead

Zhaogen Chen

Marvin M Hansen

Daniel Ray Mayhugh

Maria Ann Whatton

Jeffrey Michael Schkeryantz

Steven James Green

Daniel James Koch

Patric James Hahn

Michael Philip Cohen

Albert Khilevich

Douglas Linn Gernert

Michael Philip Mazanetz

Rushad Eruch Karanjawala

Britta Evers

Anne Marie Camp

David Joseph Garmene

Fionna Mitchell Martin

Sarah Lynne Hellman

Yen Dao

Valentina O Badescu

Kevin Michael Ruley

Yvan LeHuerou

Jeffrey Michael Witkin

John Mehnert Schaus

Barry Peter Clark

The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Disubstituted pyrazole compounds

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

A TARP &#x3b3;8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N;A is andRis as defined herein;its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

[object Object]

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently &#x2014;C(H)&#x2550; or &#x2014;N&#x2550;, provided that at least one of A and B is &#x2014;N&#x2550;, n is 1-3, m is 0-3, and R1-4 are as defined herein.

2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R, R, R, R, L, R, Rand Rare as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases. 

MCH receptor antagonists

Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C) alkylene or hydroxy substituted (C) alkylene; X is oxygen or sulfur; Ris hydrogen, (C) fluroalkyl, (C) cycloalkyl, or (C) alkyl, wherein the (C) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCHCHOH, or &#x2014;CN; Ris H, halogen, (C) fluoroalkyl, (C) cycloalkyl, OR, SR, NO, CN, COR, C(O)OR, CONRR, NRR, SONRR, NRCOR, NRSOR, optionally substituted aromatic, or (C) alkyl, wherein (C) alkyl is unsubstituted or substituted with a hydroxy group; Ris hydrogen (C) fluoroalkyl, (C) alkenyl, Ar, (C)alkyl-Ar, or (C) alkyl wherein (C) alkyly is unsubstituted or substituted with a phenyl; Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic, Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Zand Zare independently selected from hydrogen, halogen, (C) alkyl, (C) fluoroalkyl, OR, SR, NO, CN, COR, CONRR, NRR, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I) 

Piperazine substituted aryl benzodiazepines

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity 

&#x3b2;3 adrenergic agonists

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. 

Indole derivatives for the treatment of depression and anxiety

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;3 agonists

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;-3 agonists

The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine

Benzofuran derivatives

The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Tropane linked benzofuran derivatives

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Piperidines derivatives and their use as serotonin receptor antagonists

A series of dihydrophenanthreneones and tetrahydrophenanthreneones are useful as inhibitors of 5.alpha.-reductase, and a series of hexahydrophenanthreneones are useful as intermediates for preparing such pharmaceuticals.

Reduced phenanthrenes

Growing community of inventors

Avon, IN, United States of America

Patrick Gianpietro Spinazze